Across TCGA pan-cancer cohorts, MIR1261 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated MIR1261 data layer compared with 13 for mass-spec protein.
The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher MIR1261 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MIR1261 expression acts as an unfavorable survival marker.
DLBC are the cancer types where MIR1261 Mutation most reproducibly stratifies survival.